本帖最后由 老马 于 2012-1-13 21:20 编辑 ) g$ S' Y9 O2 N" O* Y# l9 R
9 y* v% o, U% S- b. N( c9 ?
爱必妥和阿瓦斯丁的比较, X2 C! u& K* Q" E! s, W3 r
( g; M$ G* p; Z( G
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
: R4 e: [, K b/ i) e# F. A
; H3 b. J$ N: V9 i4 U+ k Z
3 D- ]: T! V2 s# ~+ c+ Y, {: A
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
' y4 |7 }0 i$ r: i==================================================
! b- E! C+ N5 K! ~0 ~# v: |Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 t0 r9 G1 |$ W- F3 j
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.& I1 I1 ]/ l, e. P9 Y
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.2 H) Q) m0 y' ?8 }
|